Abstract: The invention described herein relates to a chimeric protein comprising the NTHi twitching pilus major subunit protein (PilA) presenting a portion of the NTHi OMP P5 protein. The invention provides for vaccine compositions comprising the recombinant chimeric protein and methods of eliciting an immune response using the recombinant chimeric proteins of the invention.
Type:
Grant
Filed:
October 5, 2010
Date of Patent:
September 11, 2012
Assignee:
Nationwide Children's Hospital, Inc.
Inventors:
Lauren O. Bakaletz, Robert S. Munson, Jr.
Abstract: The invention relates to the polynucleotide sequence of a nontypeable stain of Haemophilus influenzae (NTHi) and polypeptides encoded by the polynucleotides and uses thereof. The invention also relates to NTHi genes which are upregulated during or in response to NTHi infection of the middle ear and/or the nasopharynx.
Type:
Grant
Filed:
July 21, 2011
Date of Patent:
August 7, 2012
Assignee:
Nationwide Children's Hospital, Inc.
Inventors:
Lauren O. Bakaletz, Robert S. Munson, Jr., David W. Dyer
Abstract: The present invention relates to methods and materials useful for systemically delivering polynucleotides to the spinal cord. Use of the methods and materials is indicated, for example, for treatment of lower motor neuron diseases such as spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) as well as Pompe disease and lysosomal storage disorders.
Abstract: The present invention relates generally to the use of recombinant adeno-associated viruses (rAAV) for gene delivery and more specifically to the use of rAAV to deliver genes encoding human immunodeficiency virus entry inhibitors to target cells in mammals.
Type:
Application
Filed:
February 6, 2012
Publication date:
July 5, 2012
Applicant:
NATIONWIDE CHILDREN'S HOSPITAL, INC.
Inventors:
Philip R. Johnson, JR., Kelly Reed Clark
Abstract: The present invention relates to a method for treating or preventing necrotizing enterocolitis (NEC) in a human neonate in need thereof, comprising administering to the neonate a pharmaceutically effective amount of a composition comprising a poly(ADP-ribose) synthetase/polymerase (PARP) inhibitor. Also contemplated herein is an infant food or treatment composition comprising a PARP inhibitor in an amount that is 5 to 500 times greater than a daily recommended intake dosage for the PARP inhibitor.
Abstract: The invention provides for methods of protecting neurons within the enteric nervous system (ENS) comprising administering an EGF receptor agonist, such as heparin-binding EGF (HB-EGF). These methods include reducing damage of ENS neurons in patient s suffering from an intestinal injury. In addition, the invention provides for increasing intestinal motility in a patient suffering from an intestinal injury comprising administering HB-EGF. The invention also provides for methods of inducing neurite growth within the ENS in a patient suffering from intestinal injury comprising administering HB-EGF.
Abstract: The present invention relates generally to the use of recombinant adeno-associated viruses (rAAV) for gene delivery and more specifically to the use of rAAV to deliver antibody genes to target cells in mammals. Administration of rAAV encoding antibodies that neutralize the HIV-1 virus is exemplified.
Type:
Application
Filed:
July 6, 2011
Publication date:
February 2, 2012
Applicant:
NATIONWIDE CHILDREN'S HOSPITAL, INC.
Inventors:
Kelly Reed Clark, Philip R. Johnson, JR.
Abstract: The invention is related to methods of protecting, preventing and reducing intestinal injury in a human subject suffering from or at risk for shock, hemorrhagic shock or hemorrhagic shock and resuscitation (HS/R) comprising administering heparin binding epidermal growth factor (HB-EGF). The invention is also related to methods of inhibiting deterioration of intestinal blood flow and methods of preserving and increasing intestinal blood flow by administering HB-EGF to a human subject. In addition, the methods of the invention should improve the clinical outcome of human subject suffering from or at risk for shock, hemorrhagic shock or hemorrhagic shock and resuscitation.
Abstract: The present invention provides compositions and methods featuring miR-26 microRNA polynucleotides for the diagnosis, treatment or prevention of hepatic neoplasia.
Type:
Application
Filed:
December 2, 2009
Publication date:
December 8, 2011
Applicants:
Nationwide Children's Hospital, Inc, THE JOHNS HOPKINS UNIVERSITY
Inventors:
Joshua T. Mendell, Kathryn A. Mendell, Raghu R. Chivukula, Erik A. Wentzel, Jerry R. Mendell, K. Reed Clark, Janaiah Kota
Abstract: The invention relates to the polynucleotide sequence of a nontypeable stain of Haemophilus influenzae (NTHi) and polypeptides encoded by the polynucleotides and uses thereof. The invention also relates to NTHi genes which are upregulated during or in response to NTHi infection of the middle ear and/or the nasopharynx.
Type:
Application
Filed:
July 21, 2011
Publication date:
December 1, 2011
Applicant:
NATIONWIDE CHILDREN'S HOSPITAL, INC.
Inventors:
Lauren O. Bakaletz, Robert S. Munson, JR., David W. Dyer
Abstract: Methods of treating, abating and reducing the risk for necrotizing enterocolitis (NEC) in an infant are disclosed. Preferred methods include administering an EGF receptor agonist, such as HB-EGF or EGF, within 24 hours following birth or following the onset of at least one symptom of NEC, in an amount effective to reduce the onset or seventy of NEC.
Abstract: The invention relates to a mutation within the sap operon of an avirulent clone of a nontypeable strain of Haemophilus influenzae (NTHi). The invention also relates to the NTHi sap operon genes and the polypeptides encoded by these polynucleotide sequences. The invention also relates to a novel 110 kDa NTHi outer membrane protein and the polynucleotide that encodes this outer membrane protein. Methods of screening for NTHi infection, and treating and preventing NTHi related disorders are also contemplated.
Type:
Application
Filed:
March 7, 2011
Publication date:
September 15, 2011
Applicant:
Nationwide Children's Hospital, Inc.
Inventors:
Lauren O. Bakaletz, Robert S. Munson, JR.
Abstract: The invention provides materials and methods related to the use of recombinant nucleic acid molecules containing an expression control element of an inhibitor of apoptosis protein (IAP) gene operatively linked to a coding region for an active cytotoxic/cytolytic agent. The recombinant molecules are used in methods to treat a variety of diseases and disorders, including a wide range of cancers.
Abstract: The present invention relates to methods and materials for recombinant adeno-associated virus production. More particularly, in some embodiments the invention contemplates the use of an adenovirus known as Simian Adenovirus 13 (SAdV-13) and Vero cells for production of recombinant adeno-associated virus (rAAV).
Type:
Application
Filed:
April 6, 2011
Publication date:
August 18, 2011
Applicant:
NATIONWIDE CHILDREN'S HOSPITAL INC.
Inventors:
Clifford J. Beall, Kelly R. Clark, Philip R. Johnson, JR.
Abstract: The invention relates to the polynucleotide sequence of a nontypeable stain of Haemophilus influenzae (NTHi) and polypeptides encoded by the polynucleotides and uses thereof. The invention also relates to NTHi genes which are upregulated during or in response to NTHi infection of the middle ear and/or the nasopharynx.
Type:
Grant
Filed:
August 20, 2010
Date of Patent:
August 16, 2011
Assignees:
Nationwide Children's Hospital, Inc., The Board of Regents of University of Oklahoma
Inventors:
Lauren O. Bakaletz, Robert S. Munson, Jr., David W. Dyer
Abstract: The invention described herein relates to a Haemophilus influenzae (H. influenzae) regulon encoding type IV pili. In particular, the invention relates to type pili from nontypeable H. influenzae (NTHi) and from H. influenzae strains a, b, c, e and f. The invention provides isolated H. influenzae pilus polynucleotides and polypeptides encoded by the polynucleotides as well as polynucleotides and polypeptides encoded by the polynucleotides involved in the assembly/disassembly of the structure. The invention also relates to uses of these polynucleotides and/or polypeptides including methods for eliciting an immune response to H. influenzae and methods of treating and preventing H. influenzae related pathological conditions.
Type:
Application
Filed:
January 12, 2011
Publication date:
June 23, 2011
Applicant:
NATIONWIDE CHILDREN'S HOSPITAL, INC.
Inventors:
Lauren O. Bakaletz, Robert S. Munson, JR.
Abstract: The invention relates to the polynucleotide sequence of a nontypeable stain of Haemophilus influenzae (NTHi) and polypeptides encoded by the polynucleotides and uses thereof. The invention also relates to NTHi genes which are upregulated during or in response to NTHi infection of the middle ear and/or the nasopharynx.
Type:
Application
Filed:
June 15, 2006
Publication date:
June 9, 2011
Applicant:
NATIONWIDE CHILDREN'S HOSPITAL, INC.
Inventors:
Lauren O. Bakaletz, Robert S. Munson, JR., David W. Dyer
Abstract: The present invention relates to methods and materials for recombinant adeno-associated virus production. More particularly, in some embodiments the invention contemplates the use of an adenovirus known as Simian Adenovirus 13 (SAdV-13) and Vero cells for production of recombinant adeno-associated virus (rAAV).
Type:
Grant
Filed:
April 30, 2009
Date of Patent:
May 17, 2011
Assignee:
Nationwide Children's Hospital, Inc.
Inventors:
Clifford J. Beall, Kelly R. Clark, Philip R. Johnson, Jr.
Abstract: The invention described herein relates to a chimeric protein comprising the NTHi twitching pilus major subunit protein (PilA) presenting a portion of the NTHi OMP P5 protein. The invention provides for vaccine compositions comprising the recombinant chimeric protein and methods of eliciting an immune response using the recombinant chimeric proteins of the invention.
Type:
Application
Filed:
October 5, 2010
Publication date:
April 7, 2011
Applicant:
NATIONWIDE CHILDREN'S HOSPITAL, INC.
Inventors:
LAUREN O. BAKALETZ, ROBERT S. MUNSON, JR.